Xerox Holdings Corporation, together with its subsidiaries, operates as a workplace technology company that integrates hardware, services, and software for enterprises in North America, Latin America, Europe, the Middle East, Africa, India, and internationally. It operates in two segments: Print and Other, and Xerox Financial Services (XFS). The company engages in the design, development, and sale of document systems, solutions, and services, as well as associated technology offerings, including IT and software products and services. It also offers workplace solutions, which includes the sale of equipment, software, supplies, and the associated technical services; Entry, which is comprised of A4 desktop monochrome and color printers, and multifunction printers; Mid-range, which is comprised of A3 devices; and ConnectKey software. In addition, the company offers production solutions, which includes presses and solutions that provides black-and-white and full-color, as well as on-demand printing; xerographic and inkjet presses; and FreeFlow. Further, it offers Xerox services, which includes Managed Print Services, IT solutions, Capture and Content Services, and Customer Engagement Services; XFS, which offers financing for direct channel customer purchases of Xerox equipment and solutions, and lease financing to Xerox equipment and solution purchases through indirect channels; CareAR; DocuShare; and XMPie. It also invests in startups and early/mid-stage growth companies. The company sells its products through its direct sales force, distributors, independent agents, dealers, value-added resellers, systems integrators, and e-commerce marketplaces. The company was formerly known as Xerox Corporation and changed its name to Xerox Holdings Corporation in August 2019. Xerox Holdings Corporation was founded in 1903 and is headquartered in Norwalk, Connecticut.

Xerox Holdings Corporation

Piper Sandler analyst Yasmeen Rahimi maintained a Buy rating on Lexicon Pharmaceuticals today and set a price target of $6.00. Rahimi covers the He...

Lexicon Pharmaceuticals (LXRX) Receives a Buy from Piper Sandler

In a report released today, Alec Stranahan from Bank of America Securities reiterated a Hold rating on Recursion Pharmaceuticals, with a price targ...

Recursion Pharmaceuticals (RXRX) Gets a Hold from Bank of America Securities

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Lexicon Pharmaceuticals (LXRX), Ascendis Pharma (ASND) and Lanthe...

Analysts Conflicted on These Healthcare Names: Lexicon Pharmaceuticals (LXRX), Ascendis Pharma (ASND) and Lantheus (LNTH)

TD Cowen analyst Brendan Smith maintained a Hold rating on Recursion Pharmaceuticals yesterday. The company’s shares closed yesterday at $3.17. Smi...

TD Cowen Keeps Their Hold Rating on Recursion Pharmaceuticals (RXRX)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Geron (GERN), Zimmer Biomet Holdings (ZBH) and Recursion Pharmace...

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Geron (GERN), Zimmer Biomet Holdings (ZBH) and Recursion Pharmaceuticals (RXRX)

Canaccord Genuity analyst reiterated a Buy rating on Diaceutics today and set a price target of p215.00. Currently, the analyst consensus on Diaceu...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	XRX	$3.24	+0.31%	2.61M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	XRX	$3.24	+0.3%	2.61M
3
4
5
6

XRX

XRX

Get Xerox Holdings Corporation Data in Excel

Get Xerox Holdings Corporation Data in Excel